1. DOP40 Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study. (27th May 2021) Authors: Zabana Abdo, Y; Marín-Jiménez, I; Rodríguez-Lago, I; Vera, I; Martín, M D; Guerra, I; Gisbert, J P; Mesonero, F; Benítez, O; Taxonera, C; Ponferrada-Díaz, Á; Piqueras, M; Lucendo, A; Caballol, B; Mañosa, M; Martínez-Montiel, P; Bosca-Watts, M; Gordillo, J; Bujanda, L; Manceñido, N Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S078 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P437 Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry. (25th January 2019) Authors: Calafat, M; Mañosa, M; Panes, J; Nos, P; Iglesias, E; Vera, I; López-Sanromán, A; Guardiola, J; Taxonera, C; Mínguez, M; Martín, M D; de Castro, L; Riestra, S; Rivero, M; García-Planella, E; Calvet, X; García-López, S; Andreu, M; Gomollón, F; Barrio, J Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S328 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P443 Clinical features, therapeutic requirements, and evolution of patients with Crohn's disease and upper digestive tract involvement (CROHNEX study). (25th January 2019) Authors: Sainz Arnau, E; Zabana, Y; Miguel, I; Fernández Clotet, A; Casanova, M J; Martín, M D; Picó, M D; Alfambra, E; Rodriguez, I; Muñoz, F; Domínguez, M; Iglesias, E; Busquets, D; Gutiérrez, A; Cañete, F; Nuñez, L; Taxonera, C; Beltrán, B; Camps, B; Calvet, X Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S332 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗